---

---

sector : Manufacturing    symbols : PFE   

save search

---

Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors
Published: 2024-03-07 (Crawled : 12:00) - prnewswire.com
PFE | News 4 | $26.27 -0.19% 0.19% 18M |

Health Technology

| -3.38% | O: 0.04% H: 0.44% C: -1.51%
NVS | News | $98.35 1.1% 0.69% 2.1M |

Health Technology

| -4.18% | O: -2.08% H: 0.13% C: -0.57%
BMY | $48.86 -0.27% 0.98% 14M |

Health Technology

| -8.47% | O: 0.36% H: 0.34% C: -0.54%
XFOR | $1.29 4.88% 3.91% 1.6M |

Health Technology

| 33.89% | O: 0.12% H: 0.0% C: -4.98%
EYPT | News | $16.47 -6.26% -6.68% 820K |

Health Technology

| -36.01% | O: 2.56% H: 1.37% C: -4.13%
AQST | $3.9 -8.88% -9.6% 33K |

Health Technology

| -22.47% | O: 1.79% H: 12.3% C: 10.94%
ALKS | $24.65 1.61% 1.62% 600 |

Health Technology

| -14.82% | O: 1.11% H: 0.96% C: 0.65%

---

Orphan Drugs Market Projection: BCC Research Anticipates a Staggering $415.2 Billion Valuation by 2028, Reflecting Soaring Global Demand
Published: 2024-02-09 (Crawled : 10:00) - prnewswire.com
ALPMF | News | $9.5 -2.56% 43.47% 6.8K |

Health Technology

| -13.24% | O: -0.91% H: 3.88% C: 3.88%
AZNCF | News | $135.35 -3.53% -4.19% 0 |

Health Technology

| 8.28% | O: -2.6% H: 2.26% C: 1.44%
NVSEF | News | $96.0 0.94% 6.88% 0 |

Health Technology

| -7.06% | O: -2.46% H: 0.0% C: 0.0%
ALPMY | News | $9.47 -0.21% -1.11% 20K |

Manufacturing

| -11.74% | O: 4.66% H: 0.0% C: -3.92%
PFE | News 4 | $26.27 -0.19% 0.19% 18M |

Health Technology

| -4.72% | O: -0.04% H: 0.11% C: 0.0%
NVS | News | $98.35 1.1% 0.69% 2.1M |

Health Technology

| -2.97% | O: -0.37% H: 0.21% C: 0.05%
ABBV | News | $167.8 -1.03% -0.02% 2.9M |

Health Technology

| -3.8% | O: 0.33% H: 0.0% C: 0.0%
SNY | News | $46.61 -2.27% -2.21% 1.6M |

Health Technology

| 2.94% | O: 1.11% H: 0.0% C: 0.0%
AZN | News | $71.2 0.49% 0.46% 300K |

Health Technology

| 12.09% | O: -1.28% H: 1.05% C: -0.72%
research global market

---

Astellas Submits Supplemental New Drug Application in Japan for PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) for First-Line Treatment of Advanced Bladder Cancer
Published: 2024-01-31 (Crawled : 02:00) - prnewswire.com
ALPMF | News | $9.5 -2.56% 43.47% 6.8K |

Health Technology

| -17.75% | O: 4.34% H: 0.0% C: 0.0%
ALPMY | News | $9.47 -0.21% -1.11% 20K |

Manufacturing

| -18.15% | O: 0.0% H: 1.38% C: 0.26%
PFE | News 4 | $26.27 -0.19% 0.19% 18M |

Health Technology

| -2.78% | O: 0.56% H: 1.25% C: -0.33%
keytruda drug japan bladder cancer treatment application advanced

---

Astellas Announces Strategic Collaboration with Mass General Brigham
Published: 2024-01-30 (Crawled : 00:00) - prnewswire.com
ALPMF | News | $9.5 -2.56% 43.47% 6.8K |

Health Technology

| -17.75% | O: 4.34% H: 0.0% C: 0.0%
ALPMY | News | $9.47 -0.21% -1.11% 20K |

Manufacturing

| -18.15% | O: 0.0% H: 1.38% C: 0.26%
PFE | News 4 | $26.27 -0.19% 0.19% 18M |

Health Technology

| -2.78% | O: 0.56% H: 1.25% C: -0.33%
collaboration

---

Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance
Published: 2024-01-30 (Crawled : 12:30) - biospace.com/
GNMSF | News | $290.34 0.23% 3.83% 0 |

Health Technology

| 1.34% | O: 2.14% H: 1.03% C: -0.89%
ALPMF | News | $9.5 -2.56% 43.47% 6.8K |

Health Technology

| -16.3% | O: 1.76% H: 0.0% C: 0.0%
ALPMY | News | $9.47 -0.21% -1.11% 20K |

Manufacturing

| -18.36% | O: -3.53% H: 3.49% C: 3.4%
PFE | News 4 | $26.27 -0.19% 0.19% 18M |

Health Technology

| -4.4% | O: 1.49% H: 1.72% C: -3.12%
GMAB | News | $28.47 -0.32% -0.32% 420 |

Health Technology

| 0.64% | O: 0.42% H: 0.04% C: -0.99%
ARVN | $32.54 -4.29% -4.58% 0 |

Health Technology

| -17.7% | O: -0.46% H: 0.79% C: 0.28%
financial results

---

European Medicines Agency Validates Type II Variation Application for PADCEV™ (enfortumab vedotin) with KEYTRUDA®(pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Published: 2024-01-26 (Crawled : 17:00) - prnewswire.com
ALPMF | News | $9.5 -2.56% 43.47% 6.8K |

Health Technology

| -21.29% | O: -6.38% H: 0.88% C: 0.88%
ALPMY | News | $9.47 -0.21% -1.11% 20K |

Manufacturing

| -17.22% | O: 0.09% H: 0.17% C: -0.3%
PFE | News 4 | $26.27 -0.19% 0.19% 18M |

Health Technology

| -4.37% | O: 0.58% H: 1.01% C: -0.58%
keytruda bladder cancer treatment application advanced

---

EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children
Published: 2023-12-17 (Crawled : 00:00) - prnewswire.com
ALPMF | News | $9.5 -2.56% 43.47% 6.8K |

Health Technology

| -17.39% | O: 0.0% H: 0.0% C: -0.7%
ALPMY | News | $9.47 -0.21% -1.11% 20K |

Manufacturing

| -16.64% | O: 0.79% H: 0.35% C: -0.26%
UVV | $51.91 0.08% 0.58% 1.7M |

Consumer Non-Durables

| -18.02% | O: 0.0% H: 0.05% C: -1.86%
PFE | News 4 | $26.27 -0.19% 0.19% 18M |

Health Technology

| -1.35% | O: 1.09% H: 1.41% C: 0.52%
children treatment ema

---

PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer
Published: 2023-12-15 (Crawled : 22:00) - prnewswire.com
PFE | News 4 | $26.27 -0.19% 0.19% 18M |

Health Technology

| Email alert Add to watchlist
ALPMF | News | $9.5 -2.56% 43.47% 6.8K |

Health Technology

| Email alert Add to watchlist
ALPMY | News | $9.47 -0.21% -1.11% 20K |

Manufacturing

| Email alert Add to watchlist
padcev fda first approved bladder cancer treat advanced plus

---

Active Pharmaceutical Ingredients Market to Surpass $372.4 Billion, Globally, by 2030 at 6.8% CAGR: Coherent Market Insights (CMI)
Published: 2023-12-08 (Crawled : 15:00) - prnewswire.com
ENDPQ | News | $0.0007 -50.0% 1K |

n/a

| 60.0% | O: -20.0% H: 0.0% C: 0.0%
NVSEF | News | $96.0 0.94% 6.88% 0 |

Health Technology

| -0.9% | O: -1.29% H: 0.4% C: 0.4%
PPCB | $0.0011 -41.86% 5.6M |

Manufacturing

| -88.7% | O: 0.0% H: 2.61% C: -4.35%
PFE | News 4 | $26.27 -0.19% 0.19% 18M |

Health Technology

| -8.24% | O: 0.07% H: 1.1% C: 0.45%
NVS | News | $98.35 1.1% 0.69% 2.1M |

Health Technology

| 2.52% | O: 0.19% H: 0.35% C: 0.2%
active market

---

FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Published: 2023-11-30 (Crawled : 22:00) - prnewswire.com
ALPMF | News | $9.5 -2.56% 43.47% 6.8K |

Health Technology

| -19.29% | O: 3.87% H: 0.0% C: 0.0%
ALPMY | News | $9.47 -0.21% -1.11% 20K |

Manufacturing

| -22.12% | O: -3.37% H: 4.51% C: 4.51%
PFE | News 4 | $26.27 -0.19% 0.19% 18M |

Health Technology

| -13.78% | O: -4.92% H: 1.48% C: -0.21%
padcev fda license review bladder cancer treatment application grants

---

Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy
Published: 2023-11-29 (Crawled : 00:00) - prnewswire.com
ALPMY | News | $9.47 -0.21% -1.11% 20K |

Manufacturing

| -21.74% | O: 0.66% H: 0.0% C: -0.16%
PFE | News 4 | $26.27 -0.19% 0.19% 18M |

Health Technology

| -12.67% | O: 0.76% H: 0.66% C: 0.53%
women therapy hormone

---

Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting
Published: 2023-11-17 (Crawled : 04:00) - prnewswire.com
ALPMF | News | $9.5 -2.56% 43.47% 6.8K |

Health Technology

| -18.1% | O: 0.04% H: 0.0% C: 0.0%
ALPMY | News | $9.47 -0.21% -1.11% 20K |

Manufacturing

| -18.15% | O: 1.38% H: 1.79% C: 1.79%
PFE | News 4 | $26.27 -0.19% 0.19% 18M |

Health Technology

| -11.76% | O: 0.5% H: 0.3% C: 0.0%
xtandi fda approved cancer treatment

---

Oncology Drugs Market worth $520 billion by 2033 - Exclusive Report by We Market Research
Published: 2023-11-10 (Crawled : 15:00) - prnewswire.com
AZNCF | News | $135.35 -3.53% -4.19% 0 |

Health Technology

| 6.68% | O: 0.1% H: 0.0% C: -2.14%
ALPMY | News | $9.47 -0.21% -1.11% 20K |

Manufacturing

| -19.61% | O: -3.48% H: 3.87% C: 3.61%
PFE | News 4 | $26.27 -0.19% 0.19% 18M |

Health Technology

| -11.49% | O: 0.24% H: 0.22% C: -0.91%
JNJ | News | $148.53 -0.69% 0.11% 67K |

Health Technology

| -1.26% | O: -1.24% H: 0.0% C: 0.0%
BMY | $48.86 -0.27% 0.98% 14M |

Health Technology

| -3.07% | O: 0.4% H: 0.18% C: 0.0%
ABBV | News | $167.8 -1.03% -0.02% 2.9M |

Health Technology

| 21.56% | O: 0.44% H: 0.0% C: 0.0%
AZN | News | $71.2 0.49% 0.46% 300K |

Health Technology

| 11.09% | O: -1.33% H: 0.22% C: -0.11%
report research market

---

Astellas to Share New Data Across Hard-to-Treat Cancers During ESMO Congress 2023
Published: 2023-10-15 (Crawled : 00:00) - prnewswire.com
ALPMF | News | $9.5 -2.56% 43.47% 6.8K |

Health Technology

| -27.48% | O: -0.53% H: 0.0% C: 0.0%
ALPMY | News | $9.47 -0.21% -1.11% 20K |

Manufacturing

| -27.38% | O: -4.14% H: 2.4% C: 1.92%
PFE | News 4 | $26.27 -0.19% 0.19% 18M |

Health Technology

| -18.19% | O: 2.24% H: 3.32% C: 1.34%
congress

---

Global Vulvovaginal Candidiasis Treatment Market Research Report 2023-2028 - Demand for Cost-effective Vulvovaginal Candidiasis Treatment Soars with Growing Geriatric Population
Published: 2023-10-04 (Crawled : 23:00) - prnewswire.com
ALPMY | News | $9.47 -0.21% -1.11% 20K |

Manufacturing

| -29.9% | O: 0.59% H: 0.29% C: 0.22%
PFE | News 4 | $26.27 -0.19% 0.19% 18M |

Health Technology

| -21.13% | O: 0.42% H: 0.99% C: 0.06%
SCYX | $1.5 -3.23% -3.68% 88K |

Health Technology

| -32.43% | O: 0.45% H: 4.04% C: 0.45%
CDTX | News | $12.29 19.9% 14.15% 64K |

Health Technology

| 1098.92% | O: 0.39% H: 10.33% C: 3.9%
report treatment candidiasis research global growing market

---

RNA Therapeutics Market worth $18.0 billion | MarketsandMarkets
Published: 2023-09-15 (Crawled : 15:00) - prnewswire.com
SNYNF | News | $94.0 -0.27% -2.18% 0 |

Health Technology

| -13.24% | O: 1.53% H: 0.0% C: 0.0%
NVSEF | News | $96.0 0.94% 6.88% 0 |

Health Technology

| 13.27% | O: 0.79% H: 0.0% C: 0.0%
ALPMY | News | $9.47 -0.21% -1.11% 20K |

Manufacturing

| -36.82% | O: 3.0% H: 0.0% C: -3.43%
PFE | News 4 | $26.27 -0.19% 0.19% 18M |

Health Technology

| -23.07% | O: -0.26% H: 1.04% C: 0.03%
NVS | News | $98.35 1.1% 0.69% 2.1M |

Health Technology

| -3.42% | O: 1.51% H: 0.26% C: -0.72%
SRPT | $124.25 6.09% 5.75% 1.5M |

Health Technology

| 3.78% | O: -0.27% H: 0.54% C: -0.84%
SNY | News | $46.61 -2.27% -2.21% 1.6M |

Health Technology

| -13.02% | O: 0.82% H: 0.0% C: 0.0%
MRNA | News S | $108.85 0.89% 0.85% 23K |

Health Technology

| -3.51% | O: 0.16% H: 2.0% C: 1.42%
IONS | $42.45 1.46% 1.45% 730K |

Health Technology

| -2.73% | O: -0.57% H: 0.35% C: -1.11%
BNTX | News | $88.09 -0.45% -0.35% 1.9K |

Health Technology

| -22.6% | O: 0.17% H: 0.48% C: -0.82%
ARWR | $23.29 -2.06% -2.13% 810K |

Health Technology

| -23.74% | O: 0.16% H: 0.46% C: -5.46%
ALNY | $143.8 -1.55% -1.58% 400K |

Health Technology

| -25.52% | O: -0.74% H: 2.42% C: -3.47%
therapeutics market

---

European Medicines Agency Validates Type II Variation for Astellas' XTANDI® (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
Published: 2023-09-12 (Crawled : 00:00) - prnewswire.com
ALPMY | News | $9.47 -0.21% -1.11% 20K |

Manufacturing

| -36.36% | O: -0.03% H: 1.04% C: -0.37%
PFE | News 4 | $26.27 -0.19% 0.19% 18M |

Health Technology

| -23.07% | O: 0.18% H: 1.2% C: -0.38%
xtandi cancer treatment

---

FDA Grants Priority Review for XTANDI® in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
Published: 2023-08-23 (Crawled : 12:00) - biospace.com/
ALPMY | News | $9.47 -0.21% -1.11% 20K |

Manufacturing

| -37.9% | O: 0.59% H: 0.46% C: 0.46%
PFE | News 4 | $26.27 -0.19% 0.19% 18M |

Health Technology

| -28.69% | O: 0.68% H: 0.11% C: -1.16%
xtandi fda review cancer grants

---

North America Kidney Transplant Research Report 2023
Published: 2023-08-08 (Crawled : 22:00) - prnewswire.com
NVSEF | News | $96.0 0.94% 6.88% 0 |

Health Technology

| 15.65% | O: 1.11% H: 0.53% C: 0.53%
ALPMY | News | $9.47 -0.21% -1.11% 20K |

Manufacturing

| -36.91% | O: 3.93% H: 0.0% C: -3.08%
PFE | News 4 | $26.27 -0.19% 0.19% 18M |

Health Technology

| -26.29% | O: -0.11% H: 1.29% C: 0.67%
NVS | News | $98.35 1.1% 0.69% 2.1M |

Health Technology

| -4.56% | O: -0.07% H: 0.73% C: 0.36%
MDT | $80.38 -1.12% -0.03% 0 |

Health Technology

| -4.23% | O: -1.98% H: 1.7% C: 0.81%
SNY | News | $46.61 -2.27% -2.21% 1.6M |

Health Technology

| -9.14% | O: 0.81% H: 0.0% C: 0.0%
america report kidney research

---

Global CNS Therapeutics Strategic Business Report 2023: Burgeoning Global Aging Populace, Longer Life Expectancy to Drive CNS Demand
Published: 2023-06-30 (Crawled : 23:00) - prnewswire.com
ALKS | $24.65 1.61% 1.62% 600 |

Health Technology

| Email alert Add to watchlist
JNJ | News | $148.53 -0.69% 0.11% 67K |

Health Technology

| Email alert Add to watchlist
NBIX | News 4 | $138.97 -0.8% -0.85% 930K |

Health Technology

| Email alert Add to watchlist
SNYNF | News | $94.0 -0.27% -2.18% 0 |

Health Technology

| Email alert Add to watchlist
UCBJY | $64.79 -0.72% -4.38% 3.4K |

Manufacturing

| Email alert Add to watchlist
UCBJF | $128.5 -0.18% -39.66% 100 |

Health Technology

| Email alert Add to watchlist
AZNCF | News | $135.35 -3.53% -4.19% 0 |

Health Technology

| Email alert Add to watchlist
PFE | News 4 | $26.27 -0.19% 0.19% 18M |

Health Technology

| Email alert Add to watchlist
TAK | News | $13.23 -1.12% 0.0% 920K |

Health Technology

| Email alert Add to watchlist
NVSEF | News | $96.0 0.94% 6.88% 0 |

Health Technology

| Email alert Add to watchlist
NVS | News | $98.35 1.1% 0.69% 2.1M |

Health Technology

| Email alert Add to watchlist
BMY | $48.86 -0.27% 0.98% 14M |

Health Technology

| Email alert Add to watchlist
AZN | News | $71.2 0.49% 0.46% 300K |

Health Technology

| Email alert Add to watchlist
TEVJF | News | $12.37 -24.22% 380 |

Health Technology

| Email alert Add to watchlist
LLY | News | $732.2 -1.81% -0.71% 8K |

Health Technology

| Email alert Add to watchlist
SNY | News | $46.61 -2.27% -2.21% 1.6M |

Health Technology

| Email alert Add to watchlist
ABBV | News | $167.8 -1.03% -0.02% 2.9M |

Health Technology

| Email alert Add to watchlist
report business life global therapeutics

---

Gainers vs Losers

61%

39%

Top 10 Gainers

BOF | $2.08 77.78% 39.06% 110M |

BHIL | $0.1793 -4.37% 19.24% 340K |

Agriculture, Forestry, Fishing ...

UMAC | $1.48 -1.33% 14.87% 20K |

CI | $352.28 -0.11% 13.53% 2 |

Health Services

CIG.C | $2.89 -1.37% 12.8% 2.3K |

n/a

BMTX 4 | $1.545 0.98% 10.03% 2.5K |

Information

TAL | $12.26 0.57% 9.22% 12M |

Consumer Services

MTH | $154.69 -2.21% 7.56% 64 |

Consumer Durables

ASXC | $0.243 -2.41% 7.0% 1.1M |

Manufacturing

IHT P | $1.3712 0.82% 6.48% 0 |

Finance

---

Your saved searches

---